Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Fierce Pharma
Summit's global PD-1xVEGF data show new promising OS trend
With a fresh data cut in September, the death risk reduction by the ivonescimab regimen expanded to 22% with an improved nominal p value of 0.0332.
Angus Liu
Sep 7, 2025 3:30am
Fierce Pharma
Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time
Aug 26, 2025 11:36am
Prelude calls it curtains on lead SMARCA2 cancer asset
Aug 14, 2025 10:44am
Instil's licensed PD-L1xVEGF bispecific shows promise in China
Jul 31, 2025 2:10pm
Royalty signs off $2B to bankroll Revolution's RAS cancer drug
Jun 24, 2025 9:00am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
